Research Topic · Peer-Reviewed

Artificial Intelligence-based Drug Development

Artificial Intelligence (AI)-based drug development is a revolutionary method used to accelerate the drug discovery process and the development of new treatments for various diseases. AI leverages data-driven techniques, such as computer-driven analysis of large data sets, to identify potential targets for drug disc…

Curated from this journal's research 📚 2 peer-reviewed articles cited 🔖 ISSN 2768-0207 🗓 Reviewed July 2026

Overview

Artificial Intelligence (AI)-based drug development is a revolutionary method used to accelerate the drug discovery process and the development of new treatments for various diseases. AI leverages data-driven techniques, such as computer-driven analysis of large data sets, to identify potential targets for drug discovery, find new drug combinations, and develop new medicines more effectively. By leveraging the power of AI, researchers can more quickly and accurately discover potential treatments and therapies, resulting in faster and more cost-effective medical breakthroughs. AI-driven drug development also has the potential to reduce the risks associated with traditional drug discovery, such as unintended side effects or toxicity. AI-based drug development is transforming the way drugs are discovered, developed and tested, leading to an overall improvement in drug efficacy and patient outcomes.

Research published in this journal

2 peer-reviewed articles, ranked by relevance. Each links to its DOI.

Editorial oversight

Curated from peer-reviewed research published in Big Data Research (ISSN 2768-0207).

Journal editorial board
Professor Shangming Zhou · United Kingdom Professor Hong Lin · United States Dr. Rami H. Al-Rifai · United Arab Emirates

This page summarises published research for orientation; it is not medical or professional advice.